KUALA LUMPUR, 25 SEPTEMBER 2020 – Ho Wah Genting Berhad’s (“HWGB” or the “Company”) (Bursa Stock Code:9601) wholly-owned subsidiary, HWGB Biotech Sdn Bhd’s (“HWGB Biotech”) [formerly known as HWG Consortium Sdn Bhd] joint venture partner, US-based E-MO Biology Inc. (“EBI”), is in collaboration with Roderick A. Comunale II MD Inc (“Roderick Inc”) to conduct a multi centre clinical study for covid-19 prevention.
Dr. Roderick A. Comunale (“Dr. Roderick”) is currently conducting a multi-centre clinical study entitled “Inactivated Polio Vaccine (“IPV”) in prevention of COVID-19 in high risk population in a Phase IV study", to study the effects of Inactivate Polio Vaccine-IPV.
An appropriate number of volunteers, covering all age groups will be recruited after screening their medical records to ensure their eligibility to participate in the clinical study.
EBI has also submitted the finalized research protocol for approval by the United States Food and Drug Administration (“FDA”) on the use of IPV for the potential new indication, with Dr. Roderick as the principal investigator for the research protocol.
To support the research, EBI is also collaborating with America Diagnostic & Genescan Diagnostics Inc to develop a series of immunology assays needed to conduct the clinical study.
